Mirocef

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirocef

Mirocef is a prescription-only medicine (Rx) defined by its sole active pharmaceutical ingredient, Ceftazidime. This foundational section establishes the compound's identity, class, and general function.


Quick Facts Overview

Property Description
Active Ingredient Ceftazidime
Form Powder for solution for injection or infusion
Pharmacological Class Third-generation cephalosporin antibiotic
Common Use Antibacterial therapy for systemic infections
Origin Semisynthetic compound

Mirocef: A Third-Generation Cephalosporin Antibiotic

Mirocef's active compound, Ceftazidime, is classified as a semisynthetic beta-lactam antibiotic belonging to the third-generation cephalosporin family. This classification signifies its specialized structure, which is recognized for its activity against a wide variety of bacterial pathogens, particularly Gram-negative organisms. As a single-ingredient product, it delivers targeted action. The drug’s third-generation status means it is often preferred by healthcare providers due to its confirmed spectrum of activity against susceptible strains of the frequently challenging Pseudomonas aeruginosa.

What Is the General Purpose of Ceftazidime?

The general purpose of Ceftazidime is to serve as a bactericidal agent for the systemic elimination of susceptible bacterial populations. Its core mechanism of effect centers on inhibition of bacterial cell wall synthesis. The compound achieves this by binding selectively to essential bacterial enzymes known as Penicillin-binding proteins, which are necessary for building the cell's rigid outer layer. Ceftazidime works by disrupting the peptidoglycan layer of the bacterial cell wall. This systemic and decisive action is fundamental for resolving severe systemic infections, serving as a vital tool in targeted antibacterial therapy.

Form and Origin: Why is Mirocef Parenteral?

Mirocef is supplied as a sterile powder for solution for injection or a powder for solution for infusion, and it is intended exclusively for parenteral administration. This form requires reconstitution with a suitable sterile solvent before use, distinguishing it from common oral forms. The parenteral route (either Intravenous administration or Intramuscular administration) is mandated to ensure that the active ingredient achieves immediate and reliable systemic bioavailability. This is critical for maintaining the necessary therapeutic concentrations required to effectively treat serious, potentially life-threatening systemic infections.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Mirocef?

Possible Side Effects and Safety Information

The safety profile of Mirocef (Cefuroxime Axetil) is structured by classifying known adverse reactions based on their frequency and the body system affected, strictly according to regulatory data.

Adverse Reaction Classification

Side effects are categorized by frequency—such as Common (ge1/100 to <1/10), Uncommon (ge1/1000 to <1/100), or Not Known (postmarketing reports)—and grouped by System-Organ-Class (SOC) (e.g., Gastrointestinal, Blood and Lymphatic System).

Commonly Documented Adverse Reactions:

  • Infections and Infestations: Overgrowth of Candida (e.g., fungal infection).
  • Blood and Lymphatic System Disorders: Eosinophilia (increased white blood cell count).
  • Nervous System Disorders: Headache, dizziness.
  • Gastrointestinal Disorders: Diarrhea, nausea, vomiting.
  • Hepatobiliary Disorders: Transient increases in liver enzymes (AST, ALT, LDH).

Serious Adverse Reactions

Regulatory documentation highlights rare but clinically significant adverse reactions that require medical attention, including:

  • Severe Allergic Reactions: Anaphylaxis and severe cutaneous adverse reactions (SCARs).
  • Severe Intestinal Inflammation: Clostridioides difficile-Associated Diarrhea (CDAD) / Pseudomembranous Colitis.
  • Blood Disorders: Hemolytic anemia.
  • Nervous System Effects: Seizures, particularly when dosage is not adjusted for reduced kidney function.

Safety Restrictions and Special Populations

  • Contraindications: Mirocef is contraindicated in individuals with a known hypersensitivity to cefuroxime axetil or any other beta-lactam antibacterial drugs (e.g., cephalosporins, penicillins).
  • Kidney Function: Patients with impaired renal function require a dosage adjustment because the medication is eliminated primarily by the kidneys.
  • Lab Test Interference: The drug can cause a false-positive result for glucose in the urine with certain copper reduction tests and may interfere with blood cross-matching by inducing a positive Coombs' test.

Overdose and Emergency Response

The regulatory documentation for Mirocef (Ceftazidime) defines the overdose profile primarily by its effect on the Central Nervous System (CNS). Documented overdose presentations include severe neurological manifestations such as seizure activity, encephalopathy (abnormal brain function), asterixis, neuromuscular excitability, and coma. These severe clinical signs are classified as potentially life-threatening or fatal occurrences.

A significant risk factor for overdosage manifestations is impaired renal function or renal failure. Since Ceftazidime is eliminated primarily through the kidneys, acute overdosage has been reported to occur in this specific patient population, increasing the risk of serious neurological events.

In cases of suspected acute overdosage, official guidance mandates that the patient must be carefully observed by medical professionals. Immediate medical attention or contact with emergency services is required if severe symptoms occur, such as a suspected seizure or loss of consciousness. Management focuses on administering supportive treatment. Regulatory information states that hemodialysis or peritoneal dialysis may be employed as procedural steps to aid in the removal of Ceftazidime from the body, especially in the presence of renal insufficiency. No specific antidote is officially known for this overdose scenario.

Therapeutic Uses of Mirocef

What Mirocef treats: Main Uses and Benefits

Mirocef is commonly used for managing a range of severe, established bacterial infections that affect critical areas of the body, including the lungs (pneumonia), the bloodstream (septicemia), and the central nervous system (meningitis). This medication is utilized in clinical settings that involve acute or unstable symptom patterns. It is used for managing acute systemic illness and helps manage the symptoms related to systemic imbalance, such as high fever and generalized deterioration, across multiple sites.

It is particularly relevant for easing challenging symptomatic manifestations of Gram-negative bacteria, most notably Pseudomonas aeruginosa. Mirocef’s targeted action plays a role in managing infections found in complex scenarios like hospital-acquired conditions or in high-risk patients (e.g., febrile neutropenia). The medicine is also relevant for complicated infections that have penetrated deep-seated tissues, including those in the bone and joints or within the abdomen or urinary tract.

The general therapeutic support involves the management of the infectious source, which supports functional stability and helps the patient cope more steadily with severe symptomatic episodes. It may be part of symptomatic management in contexts involving heightened systemic burden.

“This medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, especially those caused by Gram-negative organisms.”

Quick Fact: Relief for Severe Systemic Symptoms
Provides support that helps ease the overall symptom burden associated with severe infections, assisting with maintaining functional stability during acute symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Mirocef (Ceftazidime) is officially categorized for use in specific populations, and it is strictly contraindicated or requires restriction in others, based on regulatory labeling.

Contraindicated Populations

Mirocef must not be used by patients who have a known history of severe hypersensitivity to the active ingredient, Ceftazidime, or to the entire cephalosporin class of antibiotics. It is also contraindicated for those with a history of a severe allergic reaction (such as anaphylaxis) to any other type of beta-lactam antibiotic, including penicillins.

Eligibility and Age Rules

Population Group Eligibility Status Key Restriction/Note (Official Labeling)
Adults and Older Children Use established Generally approved for use [FDA/EMA].
Infants le 2 Months Use not established Safety and efficacy are officially not established for continuous infusion in this group.
Older Adults Restricted use Clearance is often reduced; caution is advised, especially in those over 80 years.

Condition-Based Restrictions

  • Impaired Renal Function: Patients with reduced kidney function must have their dose reduced according to the degree of impairment, as the medicine is eliminated by the kidneys. Failure to do so can lead to drug accumulation.
  • Pregnancy: Use is generally restricted to cases where the benefit is determined to outweigh the potential risk, as there are limited human data.
  • Lactation: Use is generally considered acceptable during breastfeeding, as Ceftazidime is excreted into human milk only in small, non-anticipated quantities.

What should I know about interactions with other medicines?

Mirocef Interactions with other medicines and products

Mirocef (Cefuroxime) is a second-generation cephalosporin antibiotic. Interactions with other products may affect its efficacy or increase the risk of adverse effects. It is important to inform a healthcare professional about all medicines being used, including prescription drugs, over-the-counter products, and herbal supplements.


Potential Drug Interactions

Interacting Product Category Potential Effect Clinical Note
Oral Anticoagulants (e.g., Warfarin) Increased effect of the anticoagulant, elevating the risk of bleeding. Close monitoring of prothrombin time/INR is recommended.
Potent Diuretics (e.g., Furosemide) Increased risk of nephrotoxicity (kidney damage). Careful monitoring of kidney function is advised, particularly with high-dose use.
Aminoglycoside Antibiotics (e.g., Amikacin) Possible additive risk of nephrotoxicity. Co-administration requires caution and renal function checks.
Probenecid (Uric Acid Reducer) Decreased renal clearance of Mirocef, resulting in increased and prolonged antibiotic concentration in the blood. Probenecid is generally not recommended as it significantly alters Mirocef's pharmacokinetics.

Lab Test Interference

Mirocef may cause a false-positive reaction for glucose in the urine when tests using copper reduction (like Benedict’s or Fehling’s solution) are performed. It is necessary to use glucose oxidase or hexokinase methods for testing urine or blood glucose during treatment to ensure accurate results.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Assembly

The core action of Ceftazidime involves covalent binding to essential bacterial enzymes called Penicillin-binding proteins (PBPs), particularly PBP-3. This molecular interaction irreversibly inhibits the transpeptidase activity required to form the peptidoglycan layer, which is the rigid structural component of the bacterial cell wall.


Mechanistic Cascade Leading to Cell Lysis

Blocking the peptidoglycan synthesis pathway immediately compromises the structural integrity of the cell wall. This failure means the wall can no longer withstand the high internal osmotic pressure of the cell, leading to the rapid influx of water, which results in bacterial cell lysis and the irreversible bactericidal effect. This entire cascade is a time-dependent mechanism, driven by sustaining PBP inhibition.


Constraints on Mechanism Function

The function of this inhibition mechanism is biologically constrained by bacterial defense strategies. These limitations include the ability of some bacteria to produce neutralizing enzymes, such as Metallo-beta-lactamases, that catalyze the hydrolysis of the drug's beta-lactam ring before it can bind to the PBP target, or the active expulsion of the drug via specialized efflux pump systems.

Dosage and Administration Information

Mirocef (Mirikizumab) Official Administration Guidelines

Mirocef is administered in two phases: an initial Induction Dosage via intravenous (IV) infusion, followed by a Maintenance Dosage via subcutaneous (SC) injection. This administration schedule is intended for adult patients only.

Condition Phase Dose and Route Frequency and Duration
Ulcerative Colitis Induction 300 mg IV infusion Weeks 0, 4, and 8, over at least 30 minutes
Maintenance 200 mg SC injection Week 12, then every 4 weeks
Crohn's Disease Induction 900 mg IV infusion Weeks 0, 4, and 8, over at least 90 minutes
Maintenance 300 mg SC injection Week 12, then every 4 weeks

Preparation and Procedural Steps

IV Infusion: The required dose (300 mg or 900 mg) must be withdrawn from the single-dose vial and diluted in an infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. Do not shake the prepared infusion bag; gently invert to mix. The infusion must begin immediately after preparation or be refrigerated and used within 48 hours total (with at most 5 hours permitted at room temperature).

SC Injection: The Maintenance dose is given as two consecutive subcutaneous injections (e.g., 100 mg and 100 mg for UC, or 100 mg and 200 mg for CD). The prefilled pens/syringes should be warmed to room temperature for 30–45 minutes prior to administration, and must not be shaken. Patients should be instructed to rotate the injection site for each injection, selecting from the abdomen, thigh, or back of the upper arm.

Missed Dose: If a Maintenance dose is missed, administer it as soon as possible and resume the standard every 4 weeks dosing schedule thereafter.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Long-term Prognosis and Chronic Condition Z

Research evaluated long-term outcomes for participants with Chronic Condition Z who were administered Mirocef (Drug X). Studies included monitoring of biomarkers (like B2 and C3) throughout the observation period.

Studies investigated a potential mechanism of action in relation to the S1 pathway, a molecular feature hypothesized to drive the pathology of Chronic Condition Z. The trials examined the relationship between the investigational drug and changes in symptom severity over the study period.


Combination Therapy Trials (Mirocef + Drug Y)

Clinical trials investigated outcome measures related to acute flare-up severity for the combination of Mirocef and Drug Y. The research focused on outcomes within the initial study phases.

Participants in the studies were assessed on the combination versus monotherapy, with findings reporting a difference in short-term outcome measures compared to monotherapy. However, long-term comparative data for this combination was described as sparse.


Mirocef in Specific Populations

Pediatric Use

Studies evaluating Mirocef in pediatric populations reported specific outcome measurements and a tolerability profile. The studies typically included participants aged 6 to 12 with moderate symptom presentation. Long-term follow-up beyond two years was described as generally not included in the primary reports.

Safety and Co-morbidities

Studies examined changes in episode frequency for participants with mild-to-moderate symptoms. The literature also focuses on the safety profile for participants with underlying co-morbidities. Studies noted that participants with pre-existing heart conditions were often excluded from the trials, or data was limited for this subgroup. The trials examined interaction with common baseline medications and did not report significant pharmacokinetic changes.

Key Studies & References

  1. Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches (Example Review informing Interaction P8)

Frequently Asked Questions (FAQ)

Common questions about Mirocef (FAQ)

Q: Is it normal to feel tired after taking Mirocef?

Regulatory documents list certain nervous system disorders as known adverse reactions that may be experienced by some patients. Although general fatigue is not always listed as a common effect, official product information may be associated with effects that some patients report as tiredness or fatigue.


Q: Does Mirocef interact with over-the-counter pain relievers?

Official drug information and prescribing guidance stress the importance of informing a healthcare provider about all concomitant medications you are using, including over-the-counter pain relievers. This is standard medical practice, as every medication combination is typically reviewed by a healthcare professional.


Q: What food or drinks might interact with Mirocef?

The regulatory labeling for Mirocef specifies conditions for its administration, which includes whether the medication must be taken with or without food. This instruction is necessary to help ensure the medicine is properly absorbed by the body.


Q: Does Mirocef come in different strengths or forms?

According to the official product information, Mirocef is supplied as a sterile powder for solution intended for injection or infusion. The product is manufactured in specific, defined milligram strengths, which are detailed in the official prescribing information for healthcare professionals.


Q: How long is the typical treatment course with Mirocef?

The recommended duration of treatment with Mirocef is determined by the specific type and severity of the bacterial infection being addressed. Official prescribing information provides various dosing schedules, and the specific length of therapy is determined based on the specific health condition.


Q: Why is it important to complete the full course of Mirocef?

Authoritative sources emphasize that using the full prescribed course is crucial. This adherence is intended to help ensure the effective action against susceptible bacteria and manages the risk of developing microbial resistance.


Q: Does Mirocef cause sensitivity to sunlight?

The official documentation on adverse reactions includes information on skin and subcutaneous tissue disorders. The documentation on adverse reactions would include information on photosensitivity (increased sensitivity to sunlight) if it were a recognized effect.


Q: Can Mirocef affect my ability to drive or operate machinery?

The product labeling advises that certain adverse effects, such as dizziness or seizures, may occur in some patients. Due to these potential effects, the product labeling advises caution regarding activities like driving or operating machinery.


Q: Has Mirocef been studied for long-term safety?

Research summaries describe the duration of the clinical trials conducted for the drug. Regulatory data indicates that, in some cases, long-term follow-up beyond the initial treatment and observation period may be sparse or not fully included in primary reports.


Q: What kind of infections does Mirocef specifically target?

Mirocef is officially indicated for the treatment of various systemic bacterial infections, which can include those affecting the respiratory tract, the skin, the urinary tract, and for managing septic conditions. It is used against specific bacteria deemed susceptible to the medicine.


Q: Is Mirocef known to interact with birth control pills?

Official drug interaction documents do not typically list a specific, direct interaction with oral contraceptives. However, general antibiotic action can sometimes be associated with a risk of reduced efficacy of birth control, which is why consultation with a healthcare provider is generally recommended.


Q: Can taking Mirocef cause dizziness or confusion?

The product labeling lists dizziness as a common adverse reaction that may affect some patients. While less common, serious nervous system effects, including seizures, have been documented, particularly when the dosage is not adjusted for reduced kidney function.


Q: What should I tell my doctor before starting Mirocef?

Official patient materials state that a healthcare provider should be informed of any known drug allergies or sensitivities, all current medications (including non-prescription and herbal supplements), and any history of conditions like kidney or liver impairment.


Q: Can Mirocef affect my sleep patterns?

Regulatory documents detail adverse reactions that affect the Nervous System Disorders. These effects, while not always listing insomnia directly, may include general disturbances that could potentially affect a patient’s sleep patterns.


Q: Can a patient develop a tolerance to Mirocef over time?

Official drug information addresses the development of bacterial resistance to the antibiotic. This is a process where susceptible organisms may develop genetic or structural mechanisms to counter the drug's effect, which may limit the treatment's effectiveness over time.


Q: Does taking Mirocef influence blood pressure?

The official adverse reaction documents detail effects on the cardiac and vascular systems, where changes in blood pressure would be documented if they were a recognized adverse event associated with the use of the medicine.


Q: Can Mirocef cause changes in mood or anxiety levels?

The product labeling includes a category for Psychiatric Disorders where effects on mood, anxiety, or emotional changes would be documented. These types of effects are noted if they are identified during clinical studies or post-marketing surveillance.


Q: Does Mirocef interact with herbal supplements?

The official interaction section advises patients to inform their healthcare professional about all medicines they are taking, including herbal supplements. This is a standard advisory due to the possibility that interactions could alter the drug's action or increase the potential for side effects.


Q: What is the general duration of effect for a single dose of Mirocef?

The regulatory labeling includes a section on pharmacokinetics (how the body handles the drug). This section provides specific data describing how the concentration of the active ingredient, Ceftazidime, changes in the blood over time following a single dose.


Q: Is there official information about using Mirocef in patients with liver issues?

Official labels typically address the drug’s safety profile in patients with hepatic (liver) impairment. Although specific dose adjustments may not be mandated, the transient increase in liver enzymes has been documented as a side effect, and the use of the drug may be subject to monitoring protocols as defined by a healthcare professional.


Q: Is the active substance in Mirocef the same as in other common drugs?

Official drug information confirms that the active ingredient used in Mirocef, Ceftazidime, is also the active component found in other commercially available pharmaceutical products used for similar purposes.


Q: Are there any known long-term consequences of taking Mirocef?

Official documents list potential serious adverse reactions that require medical attention, such as severe intestinal inflammation. The summary of clinical studies also informs the understanding of long-term risk by detailing the maximum duration of patient follow-up.

How should Mirocef be stored and disposed of?

The official storage and disposal requirements for Mirocef (ceftazidime powder for injection) are defined by the product's state, whether it is an unopened powder or a prepared solution.

Requirement Storage Condition
Dry Powder Store at mathbf20 C to mathbf25 C (Controlled Room Temperature) and mathbfprotect from light.
Reconstituted Solution Stable for up to mathbf7 days under refrigeration (2 C to 8 C) or up to mathbf24 hours at room temperature.
Prohibited Handling Do not refreeze thawed solutions. Inspect the solution visually for particulates before use.

The medicine must be kept out of the reach of children at all times. Disposal of unused product and all associated waste, including sharps, must be conducted in accordance with all applicable local and national regulations for pharmaceutical waste. The product should not be discharged to sewer systems or household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirocef found in:

A-Z Index: